Autoantibodies to tumor-associated antigens: Reporters from the immune system

Immunological Reviews

Volumn 222, Issue 1, 2008, Pages 328-340

  Tan, Eng M ^a   Zhang, Jianying ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS AT EL PASO   (United States)

Author keywords

Anti TAA profiles; Auto epitope immunotherapy; Immune system reporters; TAA miniarrays; Therapeutic response monitors; Tumor associated antigens

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; AUTOANTIBODY; BINDING PROTEIN; BROXURIDINE; CORTICOSTEROID; CYCLIN B1; CYCLINE; IMMUNOSUPPRESSIVE AGENT; LA ANTIBODY; PROTEIN IMP 1; PROTEIN KOC; PROTEIN P53; PROTEIN P62; SCL 70 ANTIBODY; SOMATOMEDIN B; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RESEARCH; CANCER RISK; CARCINOGENESIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COLON CANCER; DIAGNOSTIC PROCEDURE; DISEASE PREDISPOSITION; DNA REPLICATION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE SYSTEM; IMMUNOFLUORESCENCE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER DISEASE; LUNG CANCER; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE C MYC; OVARY CANCER; PARANEOPLASTIC NEUROPATHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SCLERODERMA; SJOEGREN SYNDROME; STOMACH CANCER; T LYMPHOCYTE; TESTIS CANCER; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNITY; CANCER VACCINES; HUMANS; MICE; NEOPLASMS; RABBITS; TUMOR MARKERS, BIOLOGICAL;

EID: 41149178259     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2008.00611.x     Document Type: Review

References (97)

1. Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989 44 : 93 151.
2. Tan EM. Interactions between autoimmunity and molecular and cell biology. Bridges between clinical and basic sciences. J Clin Invest 1989 84 : 1 6.
3. Notkins A, Lernmark A. Autoimmune type 1 diabetes: resolved and unresolved issues. J Clin Invest 2001 108 : 1247 1252.
4. Rapoport B, McLachlan SM. Thyroid autoimmunity. J Clin Invest 2001 108 : 1253 1259.
5. Rose NR, Mackay IR. The Autoimmune Diseases. New York : Academic Press, 1998.
6. Whitehouse JMA, Holborow EJ. Smooth muscle antibody in malignant disease. Br Med J 1971 27 : 511 513.
7. Steiner M, Klein E, Klein G. Antinuclear reactivity of sera in patients with leukemia and other neoplastic diseases. Immunol Immunopathol 1975 4 : 373 381.
8. Nelson DS. Autoantibodies in cancer patients. Pathology 1977 9 : 155 158.
9. Thomas PJ, Kaur JS, Aitcheson CT, Robinson WA, Tan EM. Antinuclear, antinucleolar and anticytoplasmic antibodies in patients with malignant melanoma. Cancer Res 1983 43 : 1372 1380.
10. Crawford LV, Pim DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982 30 : 403 408.
11. Tan EM, Shi F-D. Relative paradigms between autoantibodies in lupus and autoantibodies in cancer. Clin Exp Immunol 2003 134 : 169 177.
12. Imai H, Nakano Y, Kiyosawa K, Tan EM. Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma. Cancer 1993 71 : 26 35.
13. Blumberg BS. Hepatitis B virus, the vaccine and the control of primary cancer of the liver. Proc Natl Acad Sci USA 1997 94 : 7121 7125.
14. Berk PD, Okuda K, Wands JR. Hepatocellular carcinoma. Semin Liver Dis 1999 19 : 233 311.
15. Imai H, Furuta K, Landberg G, Kiyosawa K, Liu FL, Tan EM. Autoantibody to DNA isomerase II in primary liver cancer. Clin Cancer Res 1995 1 : 417 424.
16. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH. Proliferation and cell cycle-dependent difference in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Diff 1991 2 : 209 214.
17. Hsiang Y-H, Wu H-Y, Liu LF. Proliferation-dependent regulation of DNA Topoisomerase II in cultured human cells. Cancer Res 1988 48 : 3230 3235.
18. Lubin R, et al. Serum p533 antibodies as early markers of lung cancer. Nat Med 1955 1 : 701 702.
19. Soussi T. P53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000 60 : 1777 1788.
20. Trivers G, et al. Anti-p53 antibodies in sers from patients with chronic obstructive pulmonary disease can predict a diagnosis of cancer. Clin Cancer Res 1996 2 : 1767 1775.
21. Trivers GE, et al. Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J Natl Cancer Inst 1995 87 : 1400 1407.
22. Royahem J, Conrad K, Frey M, Melhom J, Frank KH. Autoantibodies predictive parameters of tumor development. In : Konrad K, Humboldt RL, Meurer M, Shoenfeld Y, Tan EM, eds. Pathogenic and Diagnostic Relevance of Autoantibodies. Berlin : Pabst, 1988 : 412 414.
23. Posner JB, Dalmau J. Paraneoplastic syndromes. Curr Opin Immunol 1997 9 : 723 729.
24. Masumuru K, Darnell RB. Paraneoplastic neurologic disease antigens: RNA-binding proteins and signaling proteins in neurological degeneration. Annu Rev Neurosci 2001 24 : 239 262.
25. Keene JD. Why is Hu where? Shuttling of early response messenger RNA subsets. Proc Natl Acad Sci USA 1999 96 : 5 7.
26. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdor AF, Carbone DP. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992 52 : 4168 4174.
27. Labrecque S, Naftaly N, Thomson D, Matlas K. Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 1993 53 : 3468 3471.
28. Lubin R, Schlichtholz B, Bengoufa D, Soussi T. Analysis of p53 antibodies in patients with various cancers define B cell epitopes of human p53 on primary structure and exposure on protein surface. Cancer Res 1993 53 : 5872 5876.
29. Zhang J-Y, Chan EKL, Peng X-X, Tan EM. A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human cellular carcinoma. J Exp Med 1999 189 : 1101 1110.
30. Burd CC, Dreyfus G. Conserved structures and diversity of functions of RNA-binding proteins. Science 1994 265 : 615 621.
31. Nielsen J, Christiansen J, Lykke-Anderson J, Johnson AH, Weaver UM, Nielsen FC. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 1999 19 : 1261 1270.
32. Cariani E, et al. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors and liver cirrhosis. Cancer Res 1988 48 : 6844 6849.
33. Westley BR, May FEB. Insulin-like growth factors: the unrecognized oncogenes. Br J Cancer 1995 72 : 1065 1066.
34. Doyle GAR, Betz NA, Leeds PF, Fleisig AJ, Prokipcak RD, Ross J. The c-myc coding region determinant binding protein: a member of a family of KH domain RNA-binding proteins. Nucl Acids Res 1988 26 : 5036 5044.
35. Ioannidis P, et al. C-myc and IGF-II mRNA-binding protein (CRD-BP/IMP1) in benign and malignant mesenchymal tumors. Int J Cancer 2001 94 : 480 484.
36. Doyle GA, Bordeaux-Heller JM, Coulthard S, Meisner IF, Ross J. Amplification in human breast cancer of a gene encoding a c-myc mRNA binding protein. Cancer Res 2000 60 : 2756 2759.
37. Mueller-Pillasch F, et al. Cloning of a gene highly expressed in cancer coding for a novel KH-domain containing protein. Oncogene 1997 14 : 2729 2733.
38. Lu M, et al. Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis. Am J Pathol 2001 159 : 945 953.
39. Covini G, Chan EK, Nishioka M, Morshed SA, Reed SI, Tan EM. Immune response to cyclin B1 in hepatocellular carcinoma. Hepatology 1997 25 : 75 86.
40. Suzuki H, Graziano DF, McKolanis J, Finn OJ. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin Cancer Res 2005 11 : 1521 1526.
41. Yu M, Zhau Q, Finn OJ. Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53. Mol Immunol 2002 38 : 981 987.
42. Rinke J, Steitz JA. Precursor molecules of both human 5S ribosomal RNA and transfer RNAs are bound by a cellular protein reactive with anti-La lupus antibodies. Cell 1982 29 : 149 154.
43. Chan EKL, Francoeur AM, Tan EM. Epitopes, structural domains and asymmetry of amino acid residues in SS-B/La nuclear protein. J Immunol 1986 136 : 3744 3749.
44. Chan EKL, Tan EM. The small nuclear ribonucleoprotein SS-B/La binds RNA with a conserved protease-resistant domain of 28 kD. Mol Cell Biol 1987 7 : 2588 2591.
45. Chan EKL, Tan EM. Human autoantibody-reactive epitopes on SS-B/La are highly conserved in comparison with epitopes recognized by murine monoclonal antibodies. J Exp Med 1987 166 : 1627 1640.
46. Miyachi K, Fritzler MJ, Tan EM. Autoantibody to a nuclear antigen in proliferating cells. J Immunol 1978 139 : 2942 2946.
47. Tan C-K, Castillo C, So AG, Downey KM. An auxiliary protein for DNA polymerase delta from fetal calf thymus. J Biol Chem 1986 261 : 12310 12315.
48. Prelich C, et al. Functional identity of proliferating cell nuclear antigen and a DNA polymerase-delta auxiliary protein. Nature (London) 1987 326 : 317 320.
49. Ogata K, Ogata Y, Takasaki Y, Tan EM. Epitopes on proliferating cell nuclear antigen recognized by human lupus autoantibody and murine monoclonal antibodies. J Immunol 1987 139 : 2942 2946.
50. Huff JP, Roos G, Peebles CL, Houghten R, Sullivan KF, Tan EM. Insights into native epitopes of proliferating cell nuclear antigen using recombinant DNA protein products. J Exp Med 1990 172 : 419 429.
51. Takasaki Y, Deng JS, Tan EM. A nuclear antigen associated with cell proliferation and blast transformation. Its distribution in synchronized cells. J Exp Med 1981 154 : 1899 1909.
52. Morris GF, Mathews MB. Regulation of proliferating cell nuclear antigen during the cell cycle. J Biol Chem 1989 264 : 13856 13864.
53. Muro Y, Tsai W-M, Houghten R, Tan EM. Synthetic compound peptides simulating antigenicity of conformation-dependent autoepitopes. J Biol Chem 1994 269 : 18529 18534.
54. Laver WG, Air GM, Webster RG, Smith-Gil SJ. Epitopes on protein antigens: misconceptions and realities. Cell 1990 61 : 553 556.
55. Parry NR, Barnett PV, Ouldridge EJ, Rowland DJ, Brown F. Neutralizing epitopes of type 0 foot and mouth disease virus. II. Mapping three conformational sites with synthetic peptide reagents. J Gen Virol 1989 70 : 1493 1503.
56. Bidart J-M, et al. Peptide immunogen mimicry of a protein-specific structural epitope on human choriogonadotropin. Science 1990 248 : 736 739.
57. Richter W, Shi Y, Baekkeskov S. Autoreactive epitopes defined by diabetes-associated human monoclonal antibodies are localized to the middle and C-terminal domains of the smaller form of glutamic decarboxylase. Proc Natl Acad Sci USA 1993 90 : 2832 2836.
58. Powers AC, Bavik K, Tremble J, Daw K, Scherbaum A, Banga JP. Comparative analysis of epitope recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different autoimmune diseases. Clin Exp Immunol 1999 118 : 349 356.
59. Yang VW, Lerner MR, Steitz JA, Flint SJ. A small nuclear ribonucleoprotein is required for splicing of adenoviral early RNA sequences. Proc Natl Acad Sci USA 1981 78 : 1371 1375.
60. Shero JH, Bordwell B, Rothfield NF, Earnshaw WC. Autoantibodies to topoisomerase I are found in sera from scleroderma patients. Science 1986 231 : 737 740.
61. Guldner HH, Szostecki C, Vosberg HP, Lakomek HJ, Penner E, Bautz FA. Scl 70 autoantibodies from scleroderma patients recognize a 96 kDa protein identified as DNA topoisomerase I. Chromosoma 1986 94 : 132 138.
62. Agris PF, Parks R, Bowman L, Guenther RH, Kovacs SA, Pelsue S. Plant DNA topoisomerase I is recognized and inhibited by human Scl-70 autoantibodies. Exp Cell Res 1990 189 : 276 279.
63. Reimer G, Rose KM, Scheer U, Tan EM. Autoantibody to RNA polymerase I in scleroderma sera. J Clin Invest 1987 79 : 65 72.
64. Bunn CC, Mathews MB. Autoreactive epitope defined as the anticodon region of alanine transfer RNA. Science 1987 238 : 1116 1119.
65. Targoff IN. Autoantibodies to aminoacyl-transfer RNA synthetases fos isoleucine and glycine. Two additional synthetases are antigenic in myositis. J Immunol 1990 144 : 1737 1743.
66. Bernat RL, Borisy GG, Rothfield NF, Earnshaw WC. Injection of anticentromere antibodies in interphase disrupts events required for chromosome movement at mitosis. J Cell Biol 1990 111 : 1519 1533.
67. Tan C-K, Sullivan K, Li X, Tan EM, Downey KW, So AG. Autoantibody to the proliferating cell nuclear antigen neutralizes the activity of the auxiliary protein for DNA polymerase delta. Nucleic Acids Res 1987 15 : 9299 9308.
68. Dang CV, Tan EM, Traugh JH. Myositis autoantibody reactivity and catalytic function of threonyl-tRNA synthetase. FASEB J 1988 2 : 2376 2379.
69. Casiano CA, Martin S, Green DR, Tan EM. Selective cleavage of nuclear autoantigens during CD95 (Fas/APO-1)-mediated T cell apoptosis. J Exp Med 1996 184 : 765 770.
70. Mahoney JH, Rosen A. Apoptosis and autoimmunity. Curr Opin Immunol 2005 17 : 583 588.
71. Gaipl US, et al. Inefficient clearance of dying cells and autoreactivity. Curr Top Microbiol Immunol 2006 305 : 161 176.
72. Notman DD, Kurata N, Tan EM. Profiles of antinuclear antibodies in systemic rheumatic diseases. Ann Int Med 1975 83 : 464 469.
73. Zhang J-Y, et al. Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies. Clin Immunol 2001 100 : 149 156.
74. Zhang J-Y, Casiano C A, Peng X-X, Koziol JH, Chan EKL, Tan EM. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epid Biomarkers Prev 2003 12 : 136 143.
75. Shi F-D, et al. Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens. Prostate 2005 63 : 252 258.
76. Koziol JA, et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 2003 9 : 5120 5126.
77. Imai H, Chan EKL, Kiyosawa K, Fu X-D, Tan EM. Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma. J Clin Invest 1993 92 : 2419 2426.
78. Tureci O, Sahin U, Pfreundschuh M. Serological analysis of human tumor antigens: molecular definition and implications. Mol Med Today 1997 3 : 342 349.
79. Fernandez-Madrid F, Tang N, Alansari H, Karoonen RL, Tonkiel JE. Improved approach to identify cancer-associated autoantigens. Autoimmun Rev 2005 4 : 230 235.
80. Somers VA, et al. A panel of candidate tumor antigens in colorectal cancer revealed by serological selection of a phage displayed cDNA expression library. J Immunol 2002 169 : 2772 2780.
81. Sioud M, Hansen MH. Profiling the immune response in patients with breast cancer by phage-displayed cDNA libraries. Eur J Immunol 2001 31 : 716 725.
82. Fossa A, Alsoe L, Crameri R, Funderad S, Gaudernack G, Smeland EB. Serological cloning of cancer/testis antigen expressed in prostate cancer using a cDNA expression phage surface display. Cancer Immunol Immunother 2004 53 : 431 438.
83. Chatterjee M, et al. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res 2006 66 : 1181 1190.
84. Klade CS, et al. Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 2001 1 : 890 898.
85. Canelle L, et al. An efficient proteomics-based approach for the screening of autoantibodies. J Immunol Methods 2005 299 : 77 89.
86. Joos TO, et al. A microarray enzyme-linked immunosorbent assay for autoimmune diagnostics. Electrophoresis 2000 21 : 2641 2650.
87. Robinson WH, et al. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nature Med 2002 8 : 295 301.
88. Balboni I, Chan SM, Kattah M, Tenenbaum JD, Butte AJ, Utz PJ. Multiplexed protein array platform for analysis of autoimmune disorders. Annu Rev Immunol 2006 24 : 391 418.
89. Imai H, Kiyosawa K, Chan EKL, Tan EM. Autoantibodies in viral hepatitis-related hepatocellular carcinoma. Intervirology 1993 35 : 73 85.
90. Tan EM. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Immunol 2001 108 : 1411 1415.
91. Anderson KS, La Baer J. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res 2005 4 : 1123 1133.
92. Egloff AM, Vella LA, Finn OJ. Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Cancer Res 2006 66 : 6 9.
93. Soares MM, Mehta V, Finn OJ. Three different vaccines based on the 140-aminoacid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1 transgenic mice with different potential to tumor rejection. J Immunol 2001 166 : 6555 6563.
94. Yu Z, Restifo NP. Cancer vaccines: progress reveals new complexities. J Clin Invest 2002 110 : 289 294.
95. Pugliese A. Peptide-based treatment for autoimmune diseases: learning how to handle a doublepedged sword. J Clin Invest 2003 111 : 1280 1282.
96. Martinez NR, et al. Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide. J Clin Invest 2003 111 : 1365 1371.
97. Kao H, et al. Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med 2001 194 : 1313 1323.